Krüppel-like factor 8 (KLF8) is expressed in gliomas of different WHO grades and is essential for tumor cell proliferation

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Schnell, Oliver ^a   Romagna, Alexander ^a   Jaehnert, Irene ^a   Albrecht, Valerie ^a   Eigenbrod, Sabina ^b   Juerchott, Kathrin ^c   Kretzschmar, Hans ^b   Tonn, Jörg Christian ^a   Schichor, Christian ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c MAX PLANCK INSTITUTE OF MOLECULAR PLANT PHYSIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 8; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; KLF8 PROTEIN, HUMAN; REPRESSOR PROTEIN; SMALL INTERFERING RNA;

ANTIGEN EXPRESSION; ARTICLE; BRAIN METASTASIS; BRAIN TISSUE; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; GENE EXPRESSION REGULATION; GENE SILENCING; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MENINGIOMA; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING; ADULT; AGED; CELL PROLIFERATION; FEMALE; GENETICS; IN VITRO STUDY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADULT; AGED; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; YOUNG ADULT;

EID: 84856004299     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030429     Document Type: Article

References (20)

1. van Vliet J, Turner J, Crossley M, (2000) Human Kruppel-like factor 8: a CACCC-box binding protein that associates with CtBP and represses transcription. Nucleic Acids Res 28: 1955-1962.
2. Zhao J, Bian ZC, Yee K, Chen BP, Chien S, et al. (2003) Identification of transcription factor KLF8 as a downstream target of focal adhesion kinase in its regulation of cyclin D1 and cell cycle progression. Mol Cell 11: 1503-1515.
3. Agochiya M, Brunton VG, Owens DW, Parkinson EK, Paraskeva C, et al. (1999) Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells. Oncogene 18: 5646-5653.
4. Craven RJ, Lightfoot H, Cance WG, (2003) A decade of tyrosine kinases: from gene discovery to therapeutics. Surg Oncol 12: 39-49.
5. Zhao JJ, Roberts TM, (2006) PI3 kinases in cancer: from oncogene artifact to leading cancer target. Sci STKE pp. pe52.
6. Wang X, Zhao J, (2007) KLF8 transcription factor participates in oncogenic transformation. Oncogene 26: 456-461.
7. Fu WJ, Li JC, Wu XY, Yang ZB, Mo ZN, et al. (2010) Small interference RNA targeting Kruppel-like factor 8 inhibits the renal carcinoma 786-0 cells growth in vitro and in vivo. J Cancer Res Clin Oncol 136: 1255-1265.
8. Li JC, Yang XR, Sun HX, Xu Y, Zhou J, et al. (2010) Up-regulation of Kruppel-like factor 8 promotes tumor invasion and indicates poor prognosis for hepatocellular carcinoma. Gastroenterology:- 139: 2146-2157 e2112.
9. Wang X, Lu H, Urvalek AM, Li T, Yu L, et al. (2011) KLF8 promotes human breast cancer cell invasion and metastasis by transcriptional activation of MMP9. Oncogene 30: 1901-1911.
10. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109.
11. Schnell O, Krebs B, Wagner E, Romagna A, Beer AJ, et al. (2008) Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 18: 378-386.
12. McAnuff MA, Rettig GR, Rice KG, (2007) Potency of siRNA versus shRNA mediated knockdown in vivo. J Pharm Sci 96: 2922-2930.
13. Urvalek AM, Wang X, Lu H, Zhao J, (2010) KLF8 recruits the p300 and PCAF co-activators to its amino terminal activation domain to activate transcription. Cell Cycle 9: 601-611.
14. Johannessen AL, Torp SH, (2006) The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res 12: 143-147.
15. Torp SH, Alsaker M, (2002) Ki-67 immunoreactivity, basic fibroblastic growth factor (bFGF) expression, and microvessel density as supplementary prognostic tools in low-grade astrocytomas. An immunohistochemical study with special reference to the reliability of different Ki-67 antibodies. Pathol Res Pract 198: 261-265.
16. Hsu DW, Louis DN, Efird JT, Hedley-Whyte ET, (1997) Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol 56: 857-865.
17. Quinones-Hinojosa A, Sanai N, Smith JS, McDermott MW, (2005) Techniques to assess the proliferative potential of brain tumors. J Neurooncol 74: 19-30.
18. Wei H, Wang X, Gan B, Urvalek AM, Melkoumian ZK, et al. (2006) Sumoylation delimits KLF8 transcriptional activity associated with the cell cycle regulation. J Biol Chem 281: 16664-16671.
19. Urvalek AM, Lu H, Wang X, Li T, Yu L, et al. (2011) Regulation of the oncoprotein KLF8 by a switch between acetylation and sumoylation. Am J Transl Res 3: 121-132.
20. Eaton SA, Funnell AP, Sue N, Nicholas H, Pearson RC, et al. (2008) A network of Kruppel-like Factors (Klfs). Klf8 is repressed by Klf3 and activated by Klf1 in vivo. J Biol Chem 283: 26937-26947.